SCHEMBL21664083

SCHEMBL21664083

O=C(CNC(=O)CNC(=O)c1ccc(C2=NCCS2)s1)NCC(=O)Nc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.47
NPC1 O15118 6/20 0.43
RAB9A P51151 6/20 0.43
PPARG P37231 2/20 0.43
NCOA2 Q15596 1/20 0.43
NCOA1 Q15788 1/20 0.43
NCOA3 Q9Y6Q9 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
TP53 P04637 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21664126 1.00 TDP1 (0.47) TDP1NPC1RAB9APPARGNCOA2
SCHEMBL21663834 0.98 TDP1 (0.49) TDP1NPC1RAB9APPARGNCOA2
SCHEMBL21664100 0.73 MGLL (0.45) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL21664016 0.72 HDAC1 (0.43) NPC1RAB9AHDAC3HDAC4HDAC1
SCHEMBL21664203 0.72 HDAC1 (0.43) NPC1RAB9AHDAC3HDAC4HDAC1
SCHEMBL21663771 0.71 KMT2A (0.45) TDP1NPC1RAB9APPARGNCOA2
SCHEMBL21663775 0.71 KMT2A (0.45) TDP1NPC1RAB9APPARGNCOA2
SCHEMBL21664039 0.69 KMT2A (0.47) TDP1NPC1RAB9APPARGNCOA2
SCHEMBL20620104 0.66 MEN1 (0.66) TDP1NPC1RAB9ASMN1; SMN2TP53
SCHEMBL3050069 0.65 MEN1 (0.67) NPC1RAB9ASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319347-B2 Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound FUJIFILM CORPORATION (JP) 2022-05-03 US disclosed
US-20200040039-A1 PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND FUJIFILM CORPORATION (JP) 2020-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200040039-A1 PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND VIP, NPPA, NGLY1 TDP1 4648/4885NPC1 209/4885RAB9A 2314/4885
US-11319347-B2 Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound VIP, NPPA, NGLY1 TDP1 4648/4885NPC1 209/4885RAB9A 2314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.